Tetranectin positive expression in tumour tissue leads to longer survival in Danish women with ovarian cancer. Results from the ‘Malova’ ovarian cancer study

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS)

• Publication date

  2015-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/apm.12368PMID 25846370
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic value of tissue protein expression levels of MIB‐1 (Ki‐67) in Danish ovarian cancer patients. From the ‘MALOVA’ ovarian cancer study

  2013cited by this paper
• Limited prognostic value of tissue protein expression levels of cyclin E in Danish ovarian cancer patients: from the Danish ‘MALOVA’ ovarian cancer study

  2012cited by this paper
• 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• NORDCAN – a Nordic tool for cancer information, planning, quality control and research

  2010cited by this paper
• Identification of Tetranectin as a Potential Biomarker for Metastatic Oral Cancer

  2010cited by this paper
• Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers*S

  2009cited by this paper
• Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer

  2007cited by this paper
• Diagnosis and Management of Epithelial Ovarian Cancer

  2006cited by this paper
• Ovarian cancer in Europe: Cross‐sectional trends in incidence and mortality in 28 countries, 1953–2000

  2005cited by this paper
• Trends in the incidence and mortality of ovarian cancer in Denmark 1978–2002. Comparison with other Nordic countries

  2005cited by this paper
• Biomarkers of ovarian tumours.

  2004cited by this paper
• CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use

  2004cited by this paper
• Immunohistochemical localization of a novel, human plasma protein, tetranectin, in human endocrine tissues

  2004cited by this paper
• Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer.

  2004cited by this paper
• Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma

  2004cited by this paper
• Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis

  2004cited by this paper
• Aberrant tetranectin expression in human breast carcinomas as a predictor of survival

  2004cited by this paper
• Statistical Methods for the Analysis of Biomedical Data

  2003cited by this paper
• Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass

  2000cited by this paper
• The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer.

  2000cited by this paper
• Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass.

  2000cited by this paper
• Monoclonal antibodies against human tetranectin, epitope characterization and use in immunohistochemistry.

  1997cited by this paper
• Tetranectin, a trimeric plasminogen‐binding C‐type lectin

  1997cited by this paper
• TETRANECTIN AND PLASMIN/PLASMINOGEN ARE SIMILARLY DISTRIBUTED AT THE INVASIVE FRONT OF CUTANEOUS MELANOMA LESIONS

  1996cited by this paper
• Plasma tetranectin and colorectal cancer.

  1995cited by this paper
• Ovarian carcinoma serum markers and ovarian steroid activity--is there a link in ovarian cancer? A correlation of inhibin, tetranectin and CA-125 to ovarian activity and the gonadotropin levels.

  1995cited by this paper
• Tumor markers in the management of patients with ovarian cancer.

  1995cited by this paper
• The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors.

  1995cited by this paper
• Survival of Danish cancer patients 1943-1987. Female genital organs.

  1993cited by this paper
• The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer

  1993cited by this paper
• Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patients.

  1993cited by this paper
• Prognostic value of serum tetranectin in patients with metastatic breast cancer.

  1993cited by this paper
• Plasma tetranectin and ovarian neoplasms.

  1991cited by this paper
• Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin.

  1986cited by this paper
• Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma.

  1985cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Tetranectin and Paraoxonase-1 as Markers of Heart Failure.

  2026cites this paper
• Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment

  2025cites this paper
• Implications of CLEC3B as a Prognostic Marker in Oral Squamous Cell Carcinoma

  2024cites this paper
• Down-regulation of CLEC3B facilitates epithelial-mesenchymal transition, migration and invasion of lung adenocarcinoma cells.

  2022cites this paper
• Downregulation of exosomal CLEC3B in hepatocellular carcinoma promotes metastasis and angiogenesis via AMPK and VEGF signals

  2019cites this paper
• iTRAQ-based Comparative Serum Proteomic Analysis of Prostate Cancer Patients with or without Bone Metastasis

  2019cites this paper
• The relationship between the expression of TN and the efficiency of posterior spinal V osteotomy in patients with traumatic kyphosis

  2018cites this paper
• CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma

  2018cites this paper
• High Intratumoral Expression of Tetranectin Associates with Poor Prognosis of Patients with Gastric Cancer after Gastrectomy

  2017cites this paper